Effect of Helicobacter pylori treatment on the long-term mortality in patients with type 2 diabetes
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Meta-analyses of randomized trials reported a non-significant increase in overall mortality risk after Helicobacter pylori eradication. In this study, we investigated whether H. pylori treatment is associated with increased risk of overall mortality in patients with type 2 diabetes. Methods: In this retrospective population-based cohort study, we identified 66,706 patients treated for type 2 diabetes between 2002 and 2010 from the Korean National Health Insurance Service-National Sample Cohort. Patients who received H. pylori treatment (Hp-treatment cohort, 1,727 patients) were matched to those who did not (non-treatment cohort, 3,454 patients) at a 1:2 ratio. The primary outcome was overall mortality. The secondary outcomes were mortalities due to cardiovascular disease, cerebrovascular disease, or cancers. To estimate hazard ratio (HR) with confidential interval (CI), we used the Cox proportional-hazard model. Results: During a median follow-up of 4.7 years, the overall mortality was 5.9% (101/1,727 patients) among patients in the Hp-treatment cohort and 7.6% (364/3,454 patients) among patients in the non-treatment cohort. Adjusted HR (aHR) for overall mortality in the Hp-treatment cohort was 0.74 (95% CI, 0.59 to 0.93; p = 0.011). The mortality risks due to cardiovascular disease (aHR, 1.34; 95% CI, 0.54 to 3.30; p = 0.529), cerebrovascular disease (aHR, 0.97; 95% CI, 0.37 to 2.55; p = 0.947), and cancer (aHR, 1.08; 95% CI, 0.68 to 1.72; p = 0.742) were not significantly different between the groups. Conclusions: In type 2 diabetes patients, overall mortality did not increase after H. pylori treatment.
Abstract
Background/Aims: Meta-analyses of randomized trials reported a non-significant increase in overall mortality risk after Helicobacter pylori eradication. In this study, we investigated whether H. pylori treatment is associated with increased risk of overall mortality in patients with type 2 diabetes. Methods: In this retrospective population-based cohort study, we identified 66,706 patients treated for type 2 diabetes between 2002 and 2010 from the Korean National Health Insurance Service-National Sample Cohort. Patients who received H. pylori treatment (Hp-treatment cohort, 1,727 patients) were matched to those who did not (non-treatment cohort, 3,454 patients) at a 1:2 ratio. The primary outcome was overall mortality. The secondary outcomes were mortalities due to cardiovascular disease, cerebrovascular disease, or cancers. To estimate hazard ratio (HR) with confidential interval (CI), we used the Cox proportional-hazard model. Results: During a median follow-up of 4.7 years, the overall mortality was 5.9% (101/1,727 patients) among patients in the Hp-treatment cohort and 7.6% (364/3,454 patients) among patients in the non-treatment cohort. Adjusted HR (aHR) for overall mortality in the Hp-treatment cohort was 0.74 (95% CI, 0.59 to 0.93; p = 0.011). The mortality risks due to cardiovascular disease (aHR, 1.34; 95% CI, 0.54 to 3.30; p = 0.529), cerebrovascular disease (aHR, 0.97; 95% CI, 0.37 to 2.55; p = 0.947), and cancer (aHR, 1.08; 95% CI, 0.68 to 1.72; p = 0.742) were not significantly different between the groups. Conclusions: In type 2 diabetes patients, overall mortality did not increase after H. pylori treatment.
참고문헌 (37)
- Ford AC, "Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals:systematic review and meta-analysis of randomised controlled trials: version 2", BMJ, 348, pp.g3174~ (2014)
- Choi IJ, "Helicobacter pylori therapy for the prevention of metachronous gastric cancer", N Engl J Med, 378, pp.1085~1095 (2018)
- Gyawali B, "Does Helicobacter pylori eradication therapy to prevent gastric cancer increase all-cause mortality?", Int J Cancer, 144, pp.411~412 (2019)
- "The top 10 causes of death" (2019)[URL]
- "Mortality in the United States 2017" (2019)[URL]
- "Statistics for cause of death" (2019)[URL]
- Jespersen CM, "Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease : CLARICOR trial", BMJ, 332, pp.22~27 (2006)
- Svanstrom H, "Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study: version 2", BMJ, 349, pp.g4930~ (2014)
- Wong AY, "Cardiovascular outcomes associated with use of clarithromycin: population based study", BMJ, 352, pp.h6926~ (2016)
- American Diabetes Association, "Cardiovascular disease and risk management. Standards of Medical Care in Dia betes-2018", Diabetes Care, 41(Suppl 1), pp.S86~S104 (2018)
- Giovannucci E, "Diabetes and cancer : a consensus report", Diabetes Care, 33, pp.1674~1685 (2010)
- Lee J, "Cohort profile : the National Health Insurance Service-National Sample Cohort(NHIS-NSC), South Korea", Int J Epidemiol, 46, pp.e15~ (2017)
- World Health Organization, "ICD-10: International Statistical Classification of Diseases and Related Health Problems" (1992), World Health Organization
- Lee SS, "Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease : a nationwide cohort study in Korea", Eur Heart J, 38, pp.2599~2607 (2017)
- Kim MH, "Cumulative dose threshold for the chemopreventive effect of aspirin against gastric cancer", Am J Gastroenterol, 113, pp.845~854 (2018)
- Young-Il Kim, "Effect of Helicobacter pylori Treatment on Long-term Mortality in Patients with Hypertension", Gut and Liver, 14(1), pp.47~56 (2020), 거트앤리버 소화기연관학회협의회
- Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)
- Quan H, "Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries", Am J Epidemiol, 173, pp.676~682 (2011)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Schistosomes, "IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994", IARC Monogr Eval Carcinog Risks Hum, 61, pp.1~241 (1994)
- Hooi JKY, "Global prevalence of Helicobacter pylori infection : systematic review and meta-analysis", Gastroenterology, 153, pp.420~429 (2017)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015", Cancer Research and Treatment, 50(2), pp.303~316 (2018), 대한암학회
- Wong BC, "Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China : a randomized controlled trial", JAMA, 291, pp.187~194 (2004)
- Ma JL, "Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality", J Natl Cancer Inst, 104, pp.488~492 (2012)
- Gluud C, "Clarithromycin for 2 weeks for stable coronary heart disease : 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease", Cardiology, 111, pp.280~287 (2008)
- Winkel P, "Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial", Int J Cardiol, 182, pp.459~465 (2015)
- Cheng YJ, "The role of macrolide antibiotics in increasing cardiovascular risk", J Am Coll Cardiol, 66, pp.2173~2184 (2015)
- Mosholder AD, "Long-term risk of acute myocardial infarction, stroke, and death with outpatient use of clarithromycin : a retrospective cohort study", Am J Epidemiol, 187, pp.786~792 (2018)
- Andersen SS, "Clarithromycin use and risk of death in patients with ischemic heart disease", Cardiology, 116, pp.89~97 (2010)
- Root AA, "Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs", Br J Clin Pharmacol, 82, pp.512~521 (2016)
- Kilkkinen A, "Antibiotic use predicts an increased risk of cancer", Int J Cancer, 123, pp.2152~2155 (2008)
- Boursi B, "Recurrent antibiotic exposure may promote cancer formation: another step in understanding the role of the human microbiota?", Eur J Cancer, 51, pp.2655~2664 (2015)
- Bhatt AP, "The role of the microbiome in cancer development and therapy", CA Cancer J Clin, 67, pp.326~344 (2017)
- Garrett WS, "Cancer and the microbiota", Science, 348, pp.80~86 (2015)
- 신애선, "Increasing Trend of Colorectal Cancer Incidence in Korea, 1999-2009", Cancer Research and Treatment, 44(4), pp.219~226 (2012), 대한암학회[DOI]
- Ahn HS, "Thyroid cancer screening in south Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality", Thyroid, 26, pp.1535~1540 (2016)
- Eskin M, "Evaluation of healthy user effects with metformin and other oral antihyperglycemia medication users in adult patients with type 2diabetes", Can J Diabetes, 43, pp.322~328 (2019)